Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | HTR1D | P28221 | 5/20 | 0.37 |
| ▸ | HTR1B | P28222 | 5/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683405 | 0.92 | HTR1A (0.38) | HCRTR1HCRTR2HTR1AHTR1DHTR1B | |
| SCHEMBL874749 | 0.90 | HTR1A (0.38) | HCRTR1HCRTR2HTR1AHTR1DHTR1B | |
| SCHEMBL682043 | 0.90 | HTR1A (0.38) | HCRTR1HCRTR2HTR1AHTR1DHTR1B | |
| SCHEMBL682939 | 0.89 | PDE4B (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL873780 | 0.89 | PDE4B (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL2135884 | 0.88 | HTR1A (0.38) | HCRTR1HCRTR2HTR1AHTR1DHTR1B | |
| SCHEMBL682654 | 0.88 | HTR1A (0.38) | HCRTR1HCRTR2HTR1AHTR1DHTR1B | |
| SCHEMBL683076 | 0.84 | ALDH1A1 (0.39) | — | |
| SCHEMBL874551 | 0.83 | PDE4B (0.39) | — | |
| SCHEMBL682040 | 0.81 | TP53 (0.39) | HCRTR1HCRTR2HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HCRTR1 225/4885HCRTR2 514/4885HTR1A 491/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HCRTR1 225/4885HCRTR2 514/4885HTR1A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.